You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

100 Items
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
Exceptional Access Program
    abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
ODB - General Benefit
    dexamethasone
Jul 2018
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
Exceptional Access Program
    abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
ODB - General Benefit
    prednisone
Jul 2018
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Drugs Used:
apalutamide (Unfunded)
Nov 2018
Cancer Type: Genitourinary, Bladder / Urothelial     
Intent: Palliative
Drugs Used:
atezolizumab (Unfunded)
Dec 2018
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - For the treatment of metastatic renal cell carcinoma of clear cell histology (second-line), according to clinical criteria
Apr 2018
Cancer Type: Genitourinary, Testis     
Intent: Adjuvant, Curative
Apr 2016
Cancer Type: Genitourinary, Testis     
Intent: Adjuvant, Curative
Apr 2016
Cancer Type: Genitourinary, Testis     
Intent: Curative
Aug 2017
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
ODB - General Benefit
    bicalutamide
Nov 2017
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Oct 2016
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • bicalutamide
ODB - General Benefit
  • goserelin
Oct 2016
Cancer Type: Genitourinary, Prostate     
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • bicalutamide
ODB - General Benefit
  • leuprolide - long-acting formulation
Jun 2017